FDA Faults Baxter Oversight, Cites 4 Failings at Illinois Drug Plant

The US Food and Drug Administration has told Baxter International that management oversight of its drug manufacturing is inadequate. The finding is in a warning letter about Baxter's sterile injectable drug plant in Round Lake, Illinois. The FDA dated the letter September 29 and posted it publicly on October 20.

What happened

FDA inspectors visited the Round Lake site from March 23 to April 2, 2026. The plant makes injectable drugs, including cephalosporin antibiotics. BioSpace reports that cefazolin, vancomycin and Zosyn are among the products made there.

The letter sets out four main problems:

• Cross-contamination. Cephalosporin and other drug operations share a building but were not fully separated. Since January 2025, cephalosporin has been detected several times in multiple areas on the other side of the building.
• Sterile processing. The FDA cited weak controls to prevent microbial contamination. It noted the site has had sporadic sterility test positives since 2013.
• Laboratory and visual inspection controls. The agency said lab controls were lacking and that visual inspection operators were not properly qualified.
• Investigations. The FDA said Baxter did not fully investigate a rising trend of leaks or a 2025 cefazolin sterility failure.

On July 17, 2026, the FDA recommended a voluntary recall of one cefazolin lot and other drugs, and Baxter agreed. Fierce Pharma reports that the agency said this recall happened only after it contacted the company.

Why it matters

This is not the first warning for the site. The FDA said it discussed similar violations with Baxter at a regulatory meeting on January 15, 2025. The agency also said it has cited similar violations at other plants in Baxter's network.

According to BioSpace, Round Lake is one of Baxter's three main pharmaceutical plants and the only one of them on the US mainland.

The letter asks Baxter to hire a qualified consultant to audit its quality systems. Baxter had 15 business days to reply. If the problems are not fixed, the FDA said it may withhold approval of new applications that list the firm as a manufacturer. It also said other federal agencies may hold back contracts and that it may withhold export certificates.

A Baxter spokesperson said the company takes the warning letter seriously and is committed to addressing the issues. The company said it is implementing corrective and preventive actions at Round Lake.

What it means for people in the industry

For quality, manufacturing and regulatory staff, the letter shows the FDA holding company management responsible for repeat findings across a network of plants. The sources do not report job cuts or hiring linked to the letter. Fierce Pharma reports that the FDA also told Baxter to assess its global manufacturing operations. Things to watch are Baxter's fixes, a possible FDA reinspection and any further recalls.

See open pharma jobs in the US and Canada

Sources

• Baxter International Inc. - 733231 - 09/29/2026, US Food and Drug Administration
• FDA accuses Baxter leaders of 'inadequate' oversight after finding GMP failings, BioSpace
• FDA rebukes Baxter over 'repeated' production stumbles in new warning letter, Fierce Pharma